Aptorum Group Limited

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Retrieved on: 
Jeudi, janvier 20, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, Euronext Paris, Survival, Research, Patient, Technology, Clinical trial, MYCN, SEC, Death, Infection, United, Lists of diseases, Therapy, Cancer, JT Group Limited, FDA, Prospectus, Pharmaceutical industry, Medical imaging, EU, Science, Neuroblastoma, IND, SACT-1, Neuroblastoma, Aptorum Group Limited, SACT-1, NEUROBLASTOMA, APTORUM GROUP LIMITED

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma.
  • Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a phase 1b/2a clinical trial for SACT-1 to test the drug in neuroblastoma patients in 2022.
  • SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

Retrieved on: 
Lundi, janvier 10, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, SEC, JT Group Limited, DNA, Disease, Bacteria, Klebsiella pneumoniae, Febrile neutropenia, Technology, Patient, Research, Fungus, Parasitism, RNA, Bias, Lists of diseases, Infection, Euronext Paris, Diagnosis, Prospectus, Escherichia coli, Therapy, Virus, DNA sequencing, Mortality, Vaccine, Science, EU, Herpesviridae, Aptorum’s Rapid Pathogen Identification and Detection Diagnostics Technology (RPIDD), Aptorum Group Limited, APTORUM’S RAPID PATHOGEN IDENTIFICATION AND DETECTION DIAGNOSTICS TECHNOLOGY (RPIDD), APTORUM GROUP LIMITED

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical stage biopharmaceutical company focused on novel technologies including treatments and diagnosis of infectious diseases, announced that its subsidiary company, Aptorum Innovations Holding Limited (Aptorum Innovations), has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology (RPIDD) for the diagnosis of pathogens including viruses, bacteria, fungi and parasites.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical stage biopharmaceutical company focused on novel technologies including treatments and diagnosis of infectious diseases, announced that its subsidiary company, Aptorum Innovations Holding Limited (Aptorum Innovations), has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology (RPIDD) for the diagnosis of pathogens including viruses, bacteria, fungi and parasites.
  • Mr Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented: We are very pleased to announce this exciting update on our RPIDD technology.
  • The high sensitivity and specificity demonstrated so far further support our objective to deliver a rapid, accurate and cost-effective liquid biopsy-based technology for infectious disease diagnostics.
  • We hope that RPIDD will revolutionize traditional first line clinical diagnostics approaches that are time consuming or that fail to detect or identify disease causing pathogens.

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

Retrieved on: 
Lundi, janvier 10, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Aureus, Clinical trial, Vancomycin, Randomness, MRSA, SEC, Safety, Trial of the century, Nervous system, Single, US, JT Group Limited, Staphylococcus, Bacteria, Volunteering, Infection, Pharmacokinetics, Technology, Patient, World Health Organization, Brain, Neuroblastoma, Research, Adult, IND, ECG, Female, World, Methicillin, MAD, Staphylococcus aureus, Male, SAD, Lists of diseases, Euronext Paris, Vital signs, Prospectus, Therapy, Mortality, MYCN, Pharmaceutical industry, Science, EU, ALS-4, SACT-1, Aptorum Group Limited, ALS-4, SACT-1, APTORUM GROUP LIMITED

The safety data of the last SAD cohort (300mg) and MAD cohort (200mg twice a day for 14 days) are pending.

Key Points: 
  • The safety data of the last SAD cohort (300mg) and MAD cohort (200mg twice a day for 14 days) are pending.
  • SACT-1s first in-human clinical trial is a Phase 1, Open-label Randomized, Single Cross Over Bioavailability and Food Effect Study of SACT-1 in healthy adult volunteers.
  • Aptorum is pleased to announce the successful completion of the trial, during which no SAE were observed.
  • This milestone supports the focus of Aptorum Group to embark on the exciting Phase II clinical trials for ALS-4 and planned Phase Ib/2a clinical trials for SACT-1, subject to IND clearance.

Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance

Retrieved on: 
Mardi, septembre 8, 2020
Biotechnology, Pharmaceutical, Health, Articles, Health, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, NASDAQ, Euronext, Aptorum Group Limited, the BEAM Alliance

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the BEAM Alliance) as full member.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the BEAM Alliance) as full member.
  • We are pleased to join the BEAM Alliance and strengthen our European network with the AMR community.
  • BEAM represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.
  • For more information about BEAM Alliance, please visit https://beam-alliance.eu/
    This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models

Retrieved on: 
Mardi, septembre 1, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Articles, Health, Infectious diseases, Epidemiology, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Infection, Rare disease, Antimicrobial, Infectious disease, ALS-4, Aptorum Group Limited

ALS-4s anti-virulent properties are a novel approach in tackling antimicrobial resistance issues as encouraged by recent global action plans.

Key Points: 
  • ALS-4s anti-virulent properties are a novel approach in tackling antimicrobial resistance issues as encouraged by recent global action plans.
  • Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases, womans health and other disease areas.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
  • Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types

Retrieved on: 
Mardi, septembre 1, 2020
Biotechnology, Pharmaceutical, Health, Oncology, RTT, Brain tumor, Neuroblastoma, Cancer, Organ systems, Causes of death, SACT-1, Aptorum Group Limited

This further supports our earlier in vitro observation that SACT-1 promotes tumor DNA damage and tumor cell death.

Key Points: 
  • This further supports our earlier in vitro observation that SACT-1 promotes tumor DNA damage and tumor cell death.
  • As a result, in addition to treating neuroblastoma, SACT-1 may have potential applications in the treatment of other cancers.
  • Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases, womans health and other disease areas.
  • Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform

Retrieved on: 
Lundi, mars 30, 2020
Biotechnology, Pharmaceutical, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Patent, Health, Smart-ACT™ Platform, Aptorum Group Limited

Aptorum Group has filed patent applications on the above candidates.

Key Points: 
  • Aptorum Group has filed patent applications on the above candidates.
  • For the ongoing investigation and preclinical work, Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and also Aptorum Group has contracted with the University of Hong Kong to conduct this work.
  • Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs.
  • Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020

Retrieved on: 
Lundi, février 10, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Branches of biology, Organ systems, Brain tumor, Neuroblastoma, RTT, N-Myc, Screening, neuroblastoma, Aptorum Group Limited, Smart Pharma Group

Aptorum Group aims to screen a number of orphan disease areas including, but not limited to, oncology, autoimmune, metabolic and genetic diseases.

Key Points: 
  • Aptorum Group aims to screen a number of orphan disease areas including, but not limited to, oncology, autoimmune, metabolic and genetic diseases.
  • In our recent studies, SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent the high-risk neuroblastoma patient group.
  • Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs.
  • Smart Pharma Group conducts both computational based screening and clinical validations in advancing the development of its repurposed candidates.

Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma

Retrieved on: 
Lundi, septembre 9, 2019
Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Aptorum Group Limited, Claves Life Sciences Limited, Smart Pharma Group

Aptorum Group Limited (Nasdaq: APM) (Aptorum Group), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM) (Aptorum Group), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.
  • Under the recently-announced microbiota modulation platform operated by Aptorum Groups wholly-owned subsidiary Claves Life Sciences Limited, we have commenced the preclinical development of macromolecule candidate CLS-1 targeting the treatment of obesity.
  • Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs.
  • Smart Pharma Group conducts both computational based screening and preclinical validations in advancing the development of its repurposed candidates.

Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA

Retrieved on: 
Lundi, septembre 9, 2019
Biotechnology, Pharmaceutical, Health, General Health, Infectious diseases, Clinical trials, Infectious diseases, Medical specialties, Microbiology, Bacterial diseases, Healthcare-associated infections, Staphylococcaceae, Antibiotic-resistant bacteria, Glycopeptide antibiotics, Staphylococcus aureus, Vancomycin, Phenol-soluble modulin, ALS-4, Aptorum Group Limited

S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases1.

Key Points: 
  • S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases1.
  • MRSA and vancomycin-intermediate and resistant S. aureus have also been classified by the World Health Organization (WHO) as high priority pathogens for research and development4.
  • ALS-4 is a small molecule drug candidate that is believed to inhibit dehydrosqualene desaturase of S. aureus (incl.
  • Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs.